Alexis Ogdie, MD, MSCE
Professor of Medicine (Rheumatology) at the Hospital of the University of Pennsylvania
Director, Penn Psoriatic Arthritis Clinic, University of Pennsylvania, Philadelphia, PA
Worker Without Compensation (WOC), Philadelphia VA Medical Center, University of Pennsylvania, Philadelphia, PA
Senior Scholar, Penn Center for Clinical Epidemiology and Biostatistics
Director, Penn Center for Clinical Epidemiology and Biostatistics
Department: Medicine
Graduate Group Affiliations
Contact information
3400 Spruce Street
5 White Building
Hospital of the University of Pennsylvania
Philadelphia, PA 19104-4283
5 White Building
Hospital of the University of Pennsylvania
Philadelphia, PA 19104-4283
Office: 215-662-2454
Fax: 215-662-4500
Fax: 215-662-4500
Education:
BS
University of Minnesota, 2002.
MD
Georgetown University School of Medicine, 2006.
MSCE
University of Pennsylvania, 2012.
Permanent linkBS
University of Minnesota, 2002.
MD
Georgetown University School of Medicine, 2006.
MSCE
University of Pennsylvania, 2012.
Description of Clinical Expertise
Psoriatic Arthritis, Ankylosing Spondylitis, Spondyloarthropathies, Other Inflammatory Arthritis (e.g. Rheumatoid Arthritis)Description of Research Expertise
Psoriatic Arthritis, Axial Spondyloarthritis, Epidemiology, PharmacoepidemiologySelected Publications
McInnes IB, Coates LC, Mease PJ, Ogdie A, Kavanaugh A, Eder L, Schett G, Kivitz A, McGonagle D, Brennan N, Godwood A, Cullen E, Reich K, Ritchlin CT, Merola JF.: Sonelokimab, an IL-17A/IL-17F-inhibiting nanobody for active psoriatic arthritis: a randomized, placebo-controlled phase 2 trial. Nat Med Oct 2025.Landzberg E, Ogdie A, Yarnell C, Harhay MO, Yehya N.: Observational studies of early versus late salvage therapies in critical care exhibit intrinsic selection bias: two meta-analyses. Crit Care 29: 411, Sep 2025.
Armstrong AW, Mburu S, Gondo GC, Kornyeyeva E, Frade S, Ogdie A.: Patient Experiences with Psoriatic Disease in the USA: Results from the Psoriasis and Beyond Global Study. Drugs Real World Outcomes Aug 2025.
Mayer SE, Kluberg SA, Spence O, Oraichi D, Seifert H, Ali O, Yun H, Simon AL, Ko JS, Hugh C, Her M, Shattuck K, Jamal-Allial A, Djibo DA, Daniels K, Ma Q, McMahill-Walraven CN, Ogilvie RP, Palmsten K, Selvan M, Ziyadeh N, Ogdie A, George MD.: Effectiveness and safety of the recombinant zoster vaccine in adult patients with systemic lupus erythematosus: a claims-based retrospective cohort study in the USA. RMD Open 11: e005839, Aug 2025.
Wu A, Zhang A, Guo Y, Liu J, Yang DM, Chada LP, Ogdie A, Reddy SM, Gottlieb AB, Scher JU, Merola JF.: Comparative Risk of Infection and Prevalence of Combination Targeted Therapy in Psoriatic Arthritis. JAMA Dermatol Aug 2025.
Coates LC, Blanco R, Behrens F, Ogdie A, Van den Bosch F, Ranza R, Klionsky Y, Soliman AM, Chen M, Coombs D, Shi L, Urbanik JR, Iyile T, Lippe R, Gossec L.: Efficacy of risankizumab across GRAPPA domains in psoriatic arthritis: a pooled analysis of patients from the phase 3 KEEPsAKE 1 and 2 studies. RMD Open 11: e005522, Aug 2025.
Rice AL, Gillespie S, Sai N, Reddy SM, Merola JF, Haberman RH, Ogdie A, Scher JU.: Gaps in Documentation of Psoriatic Domains in General Rheumatologic Practices Compared to Rheumatology-Dermatology Combined Clinics. J Psoriasis Psoriatic Arthritis Jul 2025.
Thrastardottir T, Bjornsson AH, Ogdie A, Hauksdottir A, Kristinsson SY, Gudbjornsson B, Love TJ; ICEBIO.: Antimicrobial use and serious infections among psoriatic arthritis patients after initiating tumor necrosis factor inhibitors: a nationwide matched cohort study. J Rheumatol Jul 2025.
Allenzara A, Bush K, Husni ME, Reddy SM, Scher JU, Craig E, Koplin J, Walsh JA, Ogdie A.: Diverse Treatment Goals in Psoriatic Arthritis: Insights from participants in the PARC cohort. Arthritis Care Res (Hoboken) Mar 2025.
Ogdie A, Reddy SM, Gillespie SH, Husni ME, Scher JU, Salomon-Escoto K, Kay J, Luedders BA, Curtis JR, Shields AJS, Chakravarty SD, Gong C, Walsh JA.: Guselkumab versus golimumab in patients with active psoriatic arthritis and inadequate response to an initial tumor necrosis factor inhibitor: study protocol for EVOLUTION, a pragmatic, phase 3b, open-label, randomized, controlled effectiveness trial. Trials 26: 96, Mar 2025.